BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Down 15.3%

BriaCell Therapeutics Corp. (OTCMKTS:BCTXFGet Free Report) shares traded down 15.3% on Thursday . The company traded as low as $1.30 and last traded at $1.38. 347,748 shares traded hands during trading, an increase of 18,606% from the average session volume of 1,859 shares. The stock had previously closed at $1.63.

BriaCell Therapeutics Stock Performance

The stock has a 50 day moving average price of $2.46 and a two-hundred day moving average price of $3.62. The company has a market capitalization of $1.07 million, a PE ratio of -0.36 and a beta of 1.09.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.

Recommended Stories

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.